Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Feb

Today In Oncology

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

World Cancer Day 2026 UICCs Campaign United by Unique

Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer

American College of Surgeons Publishes Annual NCDB Report